Acorda to Present New Research on AMPYRA® (dalfampridine-ER) at 29th Congress of the European Committee for Treatment and

  Acorda to Present New Research on AMPYRA® (dalfampridine-ER) at 29th
  Congress of the European Committee for Treatment and Research in Multiple
  Sclerosis (ECTRIMS)

Business Wire

ARDSLEY, N.Y. -- October 2, 2013

Acorda Therapeutics, Inc.(Nasdaq:ACOR) will present new research at the 29^th
Congress of the European Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS) on AMPYRA^®(dalfampridine) Extended Release Tablets, 10
mg, an FDA-approved therapy indicated to improve walking in people with
multiple sclerosis.

“Since its approval in the U.S. three years ago, more than 150,000 people
worldwide have tried AMPYRA or FAMPYRA (the ex-U.S. brand name). This therapy
is the only treatment approved to improve walking in MS, and has become a key
therapeutic option for people with walking impairment due to multiple
sclerosis,” saidEnrique Carrazana, M.D., Acorda Therapeutics’ Chief Medical
Officer. “The new data that are being presented at ECTRIMS add to our
understanding of this important medication.”

Data being presented at ECTRIMS include:

  *Effect of dalfampridine on gait and balance in patients with multiple
    sclerosis using the NeuroCom Smart Balance Master and correlation with
    other mobility-related measures – P 245 being presented Thursday, October
    3^rd, 3:45 – 5:00pm
  *Does dalfampridine increase the risk of urinary tract infections in
    patients with multiple sclerosis? – P 717 being presented Friday, October
    4^th, 3:30 – 5:00pm

More detailed information on scientific sessions and data presentations at the
meeting can be found on the conference website:

Important Safety Information

Do not take AMPYRA if you have ever had a seizure, or have certain types of
kidney problems, or are allergic to dalfampridine (4-aminopyridine), the
active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

You could have a seizure even if you never had a seizure before. Your chance
of having a seizure is higher if you take too much AMPYRA or if your kidneys
have a mild decrease of function, which is common after age 50.

Your doctor may do a blood test to check how well your kidneys are working, if
that is not known before you start taking AMPYRA.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP,
fampridine), since the active ingredient is the same.

The most common adverse events for AMPYRA in MS patients were urinary tract
infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain,
and problems with balance.

AMPYRA may cause serious allergic reactions. Stop taking AMPYRA and call your
doctor right away or get emergency medical help if you have shortness of
breath or trouble breathing, swelling of your throat or tongue, or hives.

Please see accompanying full Prescribing Information and Patient Medication

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit, or call 1-800-FDA-1088.

About Acorda Therapeutics

Founded in 1995,Acorda Therapeuticsis a biotechnology company focused on
developing therapies that restore function and improve the lives of people
with neurological conditions.

Acorda markets threeFDA-approved therapies including:AMPYRA^®(dalfampridine)
Extended Release Tablets, 10 mg, a treatment to improve walking in patients
with multiple sclerosis (MS);ZANAFLEX CAPSULES^®(tizanidine
hydrochloride)and Zanaflex tablets, a short-acting drug for the management of
spasticity; and Qutenza^®(capsaicin) 8% Patch, for the management of
neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed
outsidethe United Statesas FAMPYRA^®(prolonged-release fampridine tablets)
byBiogen Idecunder a licensing agreement from Acorda.

Acorda has one of the leading pipelines in the industry of novel neurological
therapies. The Company is currently developing six clinical-stage therapies
and one preclinical stage therapy that address a range of disorders including
post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve
damage, spinal cord injury, neuropathic pain, and heart failure. For more
information, please visit the Company’s website

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause actual
results to differ materially, including our ability to successfully market and
sell Ampyra in the U.S.; third party payers (including governmental agencies)
may not reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results from future
studies of Ampyra or from our other research and development programs,
including Diazepam Nasal Spray or any other acquired or in-licensed programs;
we may not be able to complete development of, obtain regulatory approval for,
or successfully market Diazepam Nasal Spray or other products under
development; the occurrence of adverse safety events with our products; delays
in obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our collaboration
partner Biogen Idec in connection therewith; competition, including the impact
of generic competition on Zanaflex Capsules revenues; failure to protect our
intellectual property, to defend against the intellectual property claims of
others or to obtain third party intellectual property licenses needed for the
commercialization of our products; failure to comply with regulatory
requirements could result in adverse action by regulatory agencies; and the
ability to obtain additional financing to support our operations. These and
other risks are described in greater detail in Acorda Therapeutics' filings
with the Securities & Exchange Commission. Acorda may not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Forward-looking
statements made in this release are made only as of the date hereof, and
Acorda disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of this


Acorda Therapeutics
Jeff Macdonald, 914-326-5232
Press spacebar to pause and continue. Press esc to stop.